Advocacy intelligence hub — real-time data for patient organizations
Assistance Publique - Hôpitaux de Paris
Assiut University
Takeda
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Vega Therapeutics, Inc — PHASE3
Takeda — PHASE3
Hoffmann-La Roche — PHASE3
Hoffmann-La Roche
Assiut University
Takeda — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Alphanate
Grifols Biologicals Inc.
Humate-P
CSL Behring
Alphanate
(Antihemophilic factor (human))Orphan drugstandardGrifols Biologicals Inc.
Wilate
(von Willebrand Factor/Coagulation Factor VIII Complex (Human))Orphan drugstandardOctapharma USA, Inc.
Humate-P
(Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized)Orphan drugstandardCSL Behring
Wolfgang MIESBACH, Dr
Medizinische Klinik III, Goethe Universitat, D-60590 Frankfurt/Main (Germany)
Program Director, Clinical R&D
CSL Behring
Cristina Solomon, MD
Octapharma
guglielmo mariani, md
University of L'Aquila
Tammuella Chrisentery-Singleton, MD
ATHN, Ochsner Clinic Foundation
📍 Phoenix, Arizona
Diego Velasco Rodríguez, MD, PhD
Hospital Universitario Fundación Jiménez Díaz / IIS-FJD